Human health risk assessment of carbamazepine in surface waters of North America and Europe.

A human health risk assessment was carried out for environmental exposures to carbamazepine (CBZ) and its major human metabolites, carbamazepine diol (CBZ-DiOH) and carbamazepine N-glucuronide (CBZ-N-Glu). Carbamazepine is an active pharmaceutical ingredient (API) used worldwide as a medicine for treating epileptic seizures and trigeminal neuralgia. Carbamazepine tends to be detected in surface water more frequently, and at relatively higher concentrations, than most other APIs. Predicted no effect levels (PNECs) for CBZ and its major human metabolites were developed for surface waters to be protective of human health from environmental exposures from drinking water and fish consumption. These PNECs were compared to both measured (MEC) and predicted (PEC) environmental concentrations for North America and Europe. PECs were calculated using the geo-referenced models PhATE for North America and GREAT-ER for Europe. The combined PNEC for drinking water and fish consumption for CBZ is 226,000ng/L. Ninetieth percentile MECs ranged from 150 to 220ng/L, while 90th percentile PECs ranged from 333 to 658ng/L. Calculated margins of safety (MOS) therefore range from 340 to 1500. MOS for the major metabolites are significantly higher. This assessment indicates that CBZ and its major metabolites have high MOS (>>1) and thus should have no appreciable risk to human health through environmental exposures based on available human data.

[1]  W. Buchberger,et al.  Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry. , 2001, Journal of chromatography. A.

[2]  Sigrid Peldszus,et al.  Optimizing gas chromatographic-mass spectrometric analysis of selected pharmaceuticals and endocrine-disrupting substances in water using factorial experimental design. , 2007, Journal of chromatography. A.

[3]  Joel P Bercu,et al.  Human health risk assessments for three neuropharmaceutical compounds in surface waters. , 2008, Regulatory toxicology and pharmacology : RTP.

[4]  R. Andreozzi,et al.  Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity. , 2002, Water research.

[5]  Peter Shanahan,et al.  Screening analysis of human pharmaceutical compounds in U.S. surface waters. , 2004, Environmental science & technology.

[6]  N Kreuzinger,et al.  Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of Carbamazepine in wastewater treatment and during groundwater infiltration. , 2004, Water research.

[7]  R. Macdonald.  Carbamazepine: mechanisms of action , 1995 .

[8]  R. Erika,et al.  EU Wide Monitoring Survey of Polar Persistent Pollutants in European River Waters , 2008 .

[9]  Edward V. Sargent,et al.  A Human Health Risk Assessment of Pharmaceuticals in the Aquatic Environment , 2002 .

[10]  T. Ternes.  Occurrence of drugs in German sewage treatment plants and rivers 1 Dedicated to Professor Dr. Klaus , 1998 .

[11]  S. Kleywegt,et al.  Determination of pharmaceuticals in environmental waters by liquid chromatography/electrospray ionization/tandem mass spectrometry , 2005, Analytical and bioanalytical chemistry.

[12]  Thomas Ternes,et al.  Pharmaceuticals and Metabolites as Contaminants of the Aquatic Environment , 2001 .

[13]  D. Kolpin,et al.  A national reconnaissance of pharmaceuticals and other organic wastewater contaminants in the United States--I) groundwater. , 2008, The Science of the total environment.

[14]  Gun-Young Park,et al.  Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. , 2003, Environmental science & technology.

[15]  Frank Sacher,et al.  Removal of pharmaceuticals during drinking water treatment. , 2002, Environmental science & technology.

[16]  Tom C. J. Feijtel,et al.  Development of a geography-referenced regional exposure assessment tool for European rivers - great-er contribution to great-er #1 , 1997 .

[17]  Tom C. J. Feijtel,et al.  Development of a geography-referenced regional exposure assessment tool for European rivers—GREAT-ER , 1998 .

[18]  F. Sacher,et al.  Pharmaceuticals in groundwaters analytical methods and results of a monitoring program in Baden-Württemberg, Germany. , 2001, Journal of chromatography. A.

[19]  J N Lester,et al.  Potential Ecological and Human Health Risks Associated With the Presence of Pharmaceutically Active Compounds in the Aquatic Environment , 2004, Critical reviews in toxicology.

[20]  V. Cunningham,et al.  Effects of human pharmaceuticals on aquatic life: next steps. , 2006, Environmental science & technology.

[21]  T. Heberer.  Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. , 2002, Toxicology letters.

[22]  Adriano Joss,et al.  Removal of pharmaceuticals and fragrances in biological wastewater treatment. , 2005, Water research.

[23]  Fritz H Frimmel,et al.  Photocatalytic degradation of carbamazepine, clofibric acid and iomeprol with P25 and Hombikat UV100 in the presence of natural organic matter (NOM) and other organic water constituents. , 2005, Water research.

[24]  E. Thurman,et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. , 2002 .

[25]  Zulin Zhang,et al.  Analysis of emerging contaminants in sewage effluent and river water: comparison between spot and passive sampling. , 2008, Analytica chimica acta.

[26]  Thomas Heberer,et al.  Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents--modeling versus measurements. , 2005, Journal of hazardous materials.

[27]  R. A. Rapaport,et al.  Prediction of consumer product chemical concentrations as a function of publicly owned treatment works treatment type and riverine dilution , 1988 .

[28]  Cora J Young,et al.  Aquatic persistence of eight pharmaceuticals in a microcosm study , 2004, Environmental toxicology and chemistry.

[29]  Xiu-Sheng Miao,et al.  Carbamazepine and its metabolites in wastewater and in biosolids in a municipal wastewater treatment plant. , 2005, Environmental science & technology.

[30]  Alden K Henderson,et al.  Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant. , 2004, The Science of the total environment.

[31]  Hélène Budzinski,et al.  Multi-residue analysis of pharmaceutical compounds in aqueous samples. , 2008, Journal of chromatography. A.

[32]  Holt,et al.  The use of measured boron concentration data from the GREAT-ER UK validation study (1996-1998) to generate predicted regional boron concentrations , 2000, The Science of the total environment.

[33]  J. Faigle,et al.  Pharmacokinetic Data of Carbamazepine and Its Major Metabolites in Man , 1975 .

[34]  N. Paxéus.  Removal of selected non-steroidal anti-inflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, beta-blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment. , 2004, Water science and technology : a journal of the International Association on Water Pollution Research.

[35]  Christian G. Daughton,et al.  Pharmaceuticals and Care Products in the Environment: Scientific and Regulatory Issues , 2001 .

[36]  V. Cunningham,et al.  Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. , 2009, Regulatory toxicology and pharmacology : RTP.

[37]  J. Axelrod,et al.  Enzymatic Synthesis of N-Glucuronic Acid Conjugates , 1957, Nature.

[38]  S. Chiron,et al.  Comparing pharmaceutical and pesticide loads into a small Mediterranean river. , 2005, The Science of the total environment.

[39]  F. Christensen.  Pharmaceuticals in the environment--a human risk? , 1998, Regulatory toxicology and pharmacology : RTP.

[40]  Martin Kampmann,et al.  Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? , 2003, Water research.

[41]  P. Anderson,et al.  Human pharmaceuticals in US surface waters: a human health risk assessment. , 2005, Regulatory toxicology and pharmacology : RTP.

[42]  Jacob Gibs,et al.  Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds. , 2007, The Science of the total environment.

[43]  M. Benotti,et al.  Distributions of pharmaceuticals in an urban estuary during both dry- and wet-weather conditions. , 2007, Environmental science & technology.

[44]  Guido Fink,et al.  Simultaneous determination of psychoactive drugs and their metabolites in aqueous matrices by liquid chromatography mass Spectrometry. , 2006, Environmental science & technology.

[45]  Pippenger Ce,et al.  Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. , 1996 .

[46]  Robert S. Boethling,et al.  Improved method for estimating bioconcentration/bioaccumulation factor from octanol/water partition coefficient , 1999 .

[47]  Simon Webb,et al.  Indirect human exposure to pharmaceuticals via drinking water. , 2003, Toxicology letters.

[48]  S. L. Chang,et al.  Steady-state determination of the contribution of lung metabolism to the total body clearance of drugs: application to carbamazepine. , 1983, Journal of pharmaceutical sciences.

[49]  T. Ginn,et al.  Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. , 2005, Journal of hazardous materials.

[50]  S. Hansen,et al.  Enzymic synthesis of two glucuronides of the hydroxyisoxazole GABA-agonist, THIP, and the in vivo glucuronidation of THIP in rat. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[51]  D. Kolpin,et al.  A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States--II) untreated drinking water sources. , 2008, The Science of the total environment.